TABLE 2.
Number of participants included in the exposure–efficacy analyses by baseline renal function subgroup, with corresponding ceftolozane/tazobactam dose adjustmentsa
| Renal function subgroup | Ceftolozane, mg | Tazobactam, mg | Participants, n (%) (N = 231) |
|---|---|---|---|
| CrCl ≥15 to <30 mL/min | 500 | 250 | 11 (4.8) |
| CrCl ≥30 to ≤50 mL/min | 1000 | 500 | 19 (8.2) |
| CrCl >50 to <80 mL/min | 2000 | 1000 | 46 (19.9) |
| CrCl ≥80 to <150 mL/min | 2000 | 1000 | 109 (47.2) |
| CrCl ≥150 mL/min | 2000 | 1000 | 46 (19.9) |
a
CrCl, creatinine clearance. Doses were determined based on renal function as estimated by CrCl, which was assessed at the local laboratory. The dose for some participants was adjusted during treatment to account for changes in CrCl.